Bucinnazine is a potent and selective agonist of μ-opioid receptor (MOR) with relatively low affinity for the δ-opioid receptor and the κ-opioid receptor.
BMS-986202 is a novel Tyk2 inhibitor, binding to Tyk2 JH2, showing efficacies for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus.